
|Videos|April 29, 2020
CAR T-Cell Therapy During the COVID-19 Pandemic
Advertisement
This OncLive® webinar will focus on the impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T cells. We will feature a panel of leading experts to discuss important topics and considerations surrounding CAR T-cell therapies and the patient populations impacted during this time.
Topics:
- Resources for safe administration of CAR T-cell therapy
- Patient selection for the receipt of CAR T-cell therapy in the COVID-19 setting
- Supportive care and services for patients receiving therapy during the COVID-19 pandemic
- Impact on the continuation and enrollment of clinical trials involving CAR T-cell therapies and implications for patients
Sponsored by: Novartis
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5




































